Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birger Sørensen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Expert Opinion on Biological Therapy|May 15, 2008
Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogensMaja A Sommerfelt, Birger Sørensen
QRB Discovery|June 30, 2021
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for InfectivityBirger Sørensen, Andres Susrud, Angus George Dalgleish
Expert Opinion on Biological Therapy|March 10, 2004
Novel peptide-based HIV-1 immunotherapyMaja A Sommerfelt, Jørgen Nyhus, Birger Sørensen
Journal of Virological Methods|December 12, 2003
A simple semi-rapid HIV-1&2 confirmatory immunoassay using magnetic particlesMaja A Sommerfelt, Irene Ohlsson, Irene Flolid, et al.
AIDS Research and Human Retroviruses|December 19, 2002
Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapyBirgitta Asjö, Helen Stavang, Birger Sørensen, et al.
Scandinavian Journal of Infectious Diseases|February 21, 2012
Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven yearsAndreas Lind, Maja Sommerfelt, Jens Olof Holmberg, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|February 21, 2012
Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infectionAnne-Marte B Kran, Maja A Sommerfelt, Ingebjørg Baksaas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2003
Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremiaPål Voltersvik, Grethe Albrektsen, Elling Ulvestad, et al.
AIDS (London, England)|February 14, 2006
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cellsAnne-Marte B Kran, Birger Sørensen, Maja A Sommerfelt, et al.
Vaccine|November 18, 2005
Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Jørgen Nyhus, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Opinion on Biological Therapy|May 15, 2008
Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogensMaja A Sommerfelt, Birger Sørensen
QRB Discovery|June 30, 2021
Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for InfectivityBirger Sørensen, Andres Susrud, Angus George Dalgleish
Expert Opinion on Biological Therapy|March 10, 2004
Novel peptide-based HIV-1 immunotherapyMaja A Sommerfelt, Jørgen Nyhus, Birger Sørensen
Journal of Virological Methods|December 12, 2003
A simple semi-rapid HIV-1&2 confirmatory immunoassay using magnetic particlesMaja A Sommerfelt, Irene Ohlsson, Irene Flolid, et al.
AIDS Research and Human Retroviruses|December 19, 2002
Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapyBirgitta Asjö, Helen Stavang, Birger Sørensen, et al.
Scandinavian Journal of Infectious Diseases|February 21, 2012
Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4 + and CD8 + T cell responses lasting more than seven yearsAndreas Lind, Maja Sommerfelt, Jens Olof Holmberg, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica|February 21, 2012
Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infectionAnne-Marte B Kran, Maja A Sommerfelt, Ingebjørg Baksaas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2003
Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremiaPål Voltersvik, Grethe Albrektsen, Elling Ulvestad, et al.
AIDS (London, England)|February 14, 2006
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cellsAnne-Marte B Kran, Birger Sørensen, Maja A Sommerfelt, et al.
Vaccine|November 18, 2005
Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)Jørgen Nyhus, Anne-Marte Bakken Kran, Maja A Sommerfelt, et al.
Pageof 2